首页 | 本学科首页   官方微博 | 高级检索  
     


The effect of folic acid on the development of stomach and other gast rointestinal cancers
Authors:Zhu Shunshi  Mason Joel  Shi Yao  Hu Yunbiao  Li Rongrong  Wahg Min  Zhou Yihe  Jin Guanqiu  Xie Yuye  Wu Guiquan  Xia Dehuang  Qian Zhenhua  Sohg Hailian  Zhang Lidong  Russell Robert  Xiao Shudong
Affiliation:1. Department of Gastroenterology, The Ninth People's Hospital, Shanghai Second Medical University, Shanghai 200011, China
2. Human Nutrition Research Center on Aging, Tufts University, U.S.A.
3. The Renji Hospital and Shanghai Institute of Digestive Disease, Shanghai Second Medical University, Shanghai 200001, China
4. Shanghai First People's Hospital, Shanghai 200080, China
5. Shanghai Navy Hospital, Shanghai 200081, China
6. Shanghai Post and Telecommunication Hospital, Shanghai 200060, China
7. Shanghai Putuo People's Hospital, Shanghai 200060, China
8. Tongji University Railway Hospital, Shanghai 200072, China
9. Shanghai Traditional and Western Medical Integrated Hospital, Shanghai 200082, China
10. Ruijin Hospital Luwai Branch, Shanghai Second Medical University, Shanghai 200020, China
11. Shanghai Port Hospital, Shanghai 200010, China
Abstract:OBJECTIVE: To evaluate the roles of folic acid and beta-carotene in the chemoprevention of gastric and other gastrointestinal (GI) cancers. METHODS: In a randomized, double-blind, placebo-controlled trial, a total of 216 patients with atrophic gastritis were randomly assigned to one of the four groups: (1) folate (FA, 20 mg per day plus vitamin B(12) 1 mg, intramuscularly, per month for one year, then 20 mg two times a week plus 1 mg per three months for the next year); (2) natural beta-carotene (N-betaC, 30 mg per day for first year, then 30 mg two times a week for the next); (3) synthetic beta-carotene (S-betaC, administered as in N-betaC); and (4) placebo. Follow-ups continued from 1994 to 2001. RESULTS: A total of 7 new cases of gastrointestinal cancers were diagnosed with 3 stomach, 1 colon and 1 esophageal cancers occurring in the placebo group; 1 stomach cancer in both of the N-betaC and S-betaC groups, and no cancer occurring in FA group. In terms of GI cancers, there was a significant reduction in the FA group, compared with the placebo group (P = 0.04). A similar trend was observed in both N-betaC and S-betaC groups (P = 0.07 - 0.08). Taken together, the three intervention groups displayed a highly significant decrease in occurrence (P = 0.004, vs placebo), and a lower risk for GI cancers (OR = 0.12; 95% confidence interval, 0.03 - 0.51). For development of gastric cancer, any one of the three active-treated groups did not reach statistically significant reduction. The FA group showed obvious improvement of the gastric mucosal lesions with more patients displaying lesions reversed or stable atrophy and inflammation (P = 0.04), reversed intestinal metaplasia (P = 0.06) at the end of follow-up, and reversed displasia (P = 0.017) at 12 months. Two cases of false jaundice were found in beta-carotene groups with no influence on administration, and no side-effects were reported in FA group. CONCLUSIONS: This trial revealed the interventional effect of folic acid on the development of GI cancers, a similar effect of beta-carotene was also detected. Also, folic acid may be of use to treat atrophic gastritis by preventing or reversing the precancerous lesions.
Keywords:folic acid  β-carotene  gastritis,atrophic  stomach cancer  gastrointestinal cancer
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
点击此处可从《中华医学杂志(英文版)》浏览原始摘要信息
点击此处可从《中华医学杂志(英文版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号